Reuters logo
BRIEF-Protagonist Therapeutics reports qtrly net loss per share attributable to common stockholders $0.84
May 10, 2017 / 8:26 PM / 7 months ago

BRIEF-Protagonist Therapeutics reports qtrly net loss per share attributable to common stockholders $0.84

May 10 (Reuters) - Protagonist Therapeutics Inc

* Protagonist Therapeutics reports first quarter 2017 financial results

* Qtrly net loss per share attributable to common stockholders $0.84

* Protagonist Therapeutics - Expects current capital resources will be sufficient to fund operations through PTG-100 phase 2B top-line data Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below